Cytokinetics (CYTK) said Monday it has received acceptance for its new drug application of cardiac myosin inhibitor aficamten from the US Food and Drug Administration to treat obstructive hypertrophic cardiomyopathy.
The decision was based on Cytokinetics' pivotal phase 3 clinical study for 24 weeks of aficamten that demonstrated that the inhibitor showed "significantly improved exercise capacity" compared with placebo, the company said.
The FDA has set Sept. 26, 2025, as the Prescription Drug User Fee Act date, the company said, adding that the FDA has not planned an advisory committee meeting to discuss the application.
Shares of the company were down more than 1% in recent Monday premarket activity.
Price: 51.00, Change: -0.86, Percent Change: -1.66
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。